Correction of neuro-immune disorders in a model of post-viral chronic fatigue syndrome with an IL-1 receptor antagonist

Abstract

BACKGROUND: Chronic fatigue after a viral infection is common, and physical weakness is accompanied by cognitive impairment, leading to a decrease in the individual’s quality of life, loss of working capacity and, as a result, depression. Effective treatment methods have not yet been developed.

AIM: Therefore, the aim of this study was to identify the possibility of fatigue correction with a recombinant cytokine IL-1 receptor antagonist in an experimental model of post-viral chronic fatigue syndrome in rats.

MATERIALS AND METHODS: The work was performed on male Wistar rats; experimental chronic fatigue syndrome was induced by a single injection of polyinosinic:polycytidylic acid. We analyzed changes in behavioral reactions, the level of physical activity (degree of fatigue), changes in lactate concentration in blood and the expression of IL-1β, IL-10, INFα, 5-HTT, TLR3 genes in hypothalamus, and also assessed the splenocytes cytotoxic and proliferative activity.

RESULTS: Medication of IL-1 receptor antagonist leads to improved physical activity, a decrease in the concentration of lactat in the blood serum and a decrease in anxiety compared to untreated animals, which may indicate a milder course of chronic fatigue syndrome during the period of its maximum manifestations. Inhibition of peripheral cells of the immune system after administration of polyinosinic:polycytidylic acid and correction of this parameter with IL-1 receptor antagonist were shown. On the 10th day of the experiment, all parameters in the group of treated rats normalized and only TLR3 expression still remained elevated at the level of untreated rats which is regarded as activation of reparation processes.

CONCLUSIONS: The obtained data indicate that the use of the recombinant IL-1 receptor antagonist alleviates the manifestations of post-viral chronic fatigue syndrome in rats and completes the pathological process at an earlier date. With a recombinant IL-1 receptor antagonist is included in the treatment regimen for chronic fatigue syndrome in humans, positive results can also be expected.

Keywords

post-viral chronic fatigue syndrome / IL-1 receptor antagonist / immune system / TLR3

References

[1] Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med . 1994;121(12):953–959. doi: 10.7326/0003-4819-121-12-199412150-00009

[2] Fukuda K., Straus S.E., Hickie I., et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group // Ann Intern Med. 1994. Vol. 121, N 12. P. 953–959. doi: 10.7326/0003-4819-121-12-199412150-00009

[3] Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness . Washington (DC) : National Academies Press (US), 2015. 304 p. doi: 10.17226/19012

[4] Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington (DC): National Academies Press (US), 2015. 304 p. doi: 10.17226/19012

[5] Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med . 2002;76(1):105–115. doi: 10.1353/bhm.2002.0022

[6] Johnson N.P., Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic // Bull Hist Med. 2002. Vol. 76, N 1. P. 105–115. doi: 10.1353/bhm.2002.0022

[7] Magnus P, Gunnes N, Tveito K, et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine . 2015;33(46):6173–6177. doi: 10.1016/j.vaccine.2015.10.018

[8] Magnus P., Gunnes N., Tveito K., et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine // Vaccine. 2015. Vol. 33, N 46. P. 6173–6177. doi: 10.1016/j.vaccine.2015.10.018

[9] Wilson HW, Amo-Addae M, Kenu E, et al. Post-Ebola syndrome among Ebola virus disease survivors in Montserrado county, Liberia 2016. Biomed Res Int . 2018;2018:1909410. doi: 10.1155/2018/1909410

[10] Wilson H.W., Amo-Addae M., Kenu E., et al. Post-Ebola syndrome among Ebola virus disease survivors in Montserrado county, Liberia 2016 // Biomed Res Int. 2018. Vol. 2018. P. 1909410. doi: 10.1155/2018/1909410

[11] White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry . 1998;173:475–481 . doi: 10.1192/bjp.173.6.475

[12] White P.D., Thomas J.M., Amess J., et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever // Br J Psychiatry. 1998. Vol. 173. P. 475–481. doi: 10.1192/bjp.173.6.475

[13] Katz BZ, Shiraishi Y, Mears CJ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics . 2009;124(1):189–193. doi: 10.1542/peds.2008-1879

[14] Katz B.Z., Shiraishi Y., Mears C.J., et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents // Pediatrics. 2009. Vol. 124, N 1. P. 189–193. doi: 10.1542/peds.2008-1879

[15] Campos MC, Nery T, Starke AC, et al. Post-viral fatigue in COVID -19: A review of symptom assessment methods, mental, cognitive, and physical impairment. Neurosci Biobehav Rev . 2022;142:104902. doi: 10.1016/j.neubiorev.2022.104902

[16] Campos M.C., Nery T., Starke A.C., et al. Post-viral fatigue in COVID -19: A review of symptom assessment methods, mental, cognitive, and physical impairment // Neurosci Biobehav Rev. 2022. Vol. 142. P. 104902. doi: 10.1016/j.neubiorev.2022.104902

[17] Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study. J Nucl Med . 2014;55(6):945–950. doi: 10.2967/jnumed.113.131045

[18] Nakatomi Y., Mizuno K., Ishii A., et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study // J Nucl Med. 2014. Vol. 55, N 6. P. 945–950. doi: 10.2967/jnumed.113.131045

[19] Rhoades R, Solomon S, Johnson C, Teng S. Impact of SARS-CoV-2 on host factors involved in mental disorders. Front Microbiol . 2022;13:845559. doi: 10.3389/fmicb.2022.845559

[20] Rhoades R., Solomon S., Johnson C., Teng S. Impact of SARS-CoV-2 on host factors involved in mental disorders // Front Microbiol. 2022. Vol. 13. P. 845559. doi: 10.3389/fmicb.2022.845559

[21] Mondelli V, Pariante CM. What can neuroimmunology teach us about the symptoms of long-COVID? Oxf Open Immunol . 2021;2(1):iqab004. doi: 10.1093/oxfimm/iqab004

[22] Mondelli V., Pariante C.M. What can neuroimmunology teach us about the symptoms of long-COVID? // Oxf Open Immunol. 2021. Vol. 2, N 1. P. iqab004. doi: 10.1093/oxfimm/iqab004

[23] Katafuchi T, Kondo T, Yasaka T, et al. Prolonged effects of polyriboinosinic: polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neuroscience . 2003;120(3):837–845 . doi: 10.1016/s0306-4522(03)00365-8

[24] Katafuchi T., Kondo T., Yasaka T., et al. Prolonged effects of polyriboinosinic: polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue // Neuroscience. 2003. Vol. 120, N 3. P. 837–845. doi: 10.1016/s0306-4522(03)00365-8

[25] Roerink ME, van der Schaaf ME, Dinarello CA, et al. Interleukin-1 as a mediator of fatigue in disease: a narrative review. J Neuroinflammation . 2017;14(1):16. doi: 10.1186/s12974-017-0796-7

[26] Roerink M.E., van der Schaaf M.E., Dinarello C.A., et al. Interleukin-1 as a mediator of fatigue in disease: a narrative review // J Neuroinflammation. 2017. Vol. 14, N 1. P. 16. doi: 10.1186/s12974-017-0796-7

[27] Yamato M, Tamura Y, Eguchi A, et al. Brain interleukin-1β and the intrinsic receptor antagonist control peripheral Toll-like receptor 3-mediated suppression of spontaneous activity in rats. PLoS One . 2014;9(3):e90950. doi: 10.1371/journal.pone.0090950

[28] Yamato M., Tamura Y., Eguchi A., et al. Brain interleukin-1β and the intrinsic receptor antagonist control peripheral Toll-like receptor 3-mediated suppression of spontaneous activity in rats // PLoS One. 2014. Vol. 9, N 3. P. e90950. doi: 10.1371/journal.pone.0090950

[29] Woodlock TJ, Sahasrabudhe DM, Marquis DM, et al. Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immunother . 1999;22(3):251–259. doi: 10.1097/00002371-199905000-00008

[30] Woodlock T.J., Sahasrabudhe D.M., Marquis D.M., et al. Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha // J Immunother. 1999. Vol. 22, N 3. P. 251–259. doi: 10.1097/00002371-199905000-00008

[31] Rinehart J, Hersh E, Issell B, et al. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940. Cancer Invest . 1997;15(5):403–410. doi: 10.3109/07357909709047578

[32] Rinehart J., Hersh E., Issell B., et al. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940 // Cancer Invest. 1997. Vol. 15, N 5. P. 403–410. doi: 10.3109/07357909709047578

[33] Weisdorf D, Katsanis E, Verfaillie C, et al. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. Blood . 1994;84(6):2044–2049.

[34] Weisdorf D., Katsanis E., Verfaillie C., et al. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial // Blood. 1994. Vol. 84, N 6. P. 2044–2049.

[35] Noda M, Ifuku M, Hossain MS, Katafuchi T. Glial activation and expression of the serotonin transporter in chronic fatigue syndrome. Front Psychiatry . 2018;9:589. doi: 10.3389/fpsyt.2018.00589

[36] Noda M., Ifuku M., Hossain M.S., Katafuchi T. Glial activation and expression of the serotonin transporter in chronic fatigue syndrome // Front Psychiatry. 2018. Vol. 9. P. 589. doi: 10.3389/fpsyt.2018.00589

[37] Newell EA, Todd BP, Mahoney J, et al. Combined blockade of interleukin-1α and -1β signaling protects mice from cognitive dysfunction after traumatic brain injury. eNeuro . 2018;5(2):ENEURO.0385–17.2018. doi:10.1523/ENEURO.0385-17.2018

[38] Newell E.A., Todd B.P., Mahoney J., et al. Combined blockade of interleukin-1α and -1β signaling protects mice from cognitive dysfunction after traumatic brain injury // eNeuro. 2018. Vol. 5, N 2. P. ENEURO.0385–17.2018. doi:10.1523/ENEURO.0385-17.2018

[39] Liu X, Yamashita T, Chen Q, et al. Interleukin 1 type 1 receptor restore: a genetic mouse model for studying interleukin 1 receptor-mediated effects in specific cell types. J Neurosci . 2015;35(7):2860–2870. doi: 10.1523/JNEUROSCI.3199-14.2015

[40] Liu X., Yamashita T., Chen Q., et al. Interleukin 1 type 1 receptor restore: a genetic mouse model for studying interleukin 1 receptor-mediated effects in specific cell types // J Neurosci. 2015. Vol. 35, N 7. P. 2860–2870. doi: 10.1523/JNEUROSCI.3199-14.2015

[41] Thome JG, Reeder EL, Collins SM, et al. Contributions of interleukin-1 receptor signaling in traumatic brain injury. Front Behav Neurosci . 2020;13:287. doi: 10.3389/fnbeh.2019.00287

[42] Thome J.G., Reeder E.L., Collins S.M., et al. Contributions of interleukin-1 receptor signaling in traumatic brain injury // Front Behav Neurosci. 2020. Vol. 13. P. 287. doi: 10.3389/fnbeh.2019.00287

[43] Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther. 2004;26(12):1960–1975. doi: 10.1016/j.clinthera.2004.12.019

[44] Furst D.E. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis // Clin Ther. 2004. Vol. 26, N 12. P. 1960–1975. doi: 10.1016/j.clinthera.2004.12.019

[45] Fomicheva EE, Shanin SN, Filatenkova TA, et al. Correction of behavioral disorders and state of microglia with a recombinant IL-1 receptor antagonist in experimental traumatic brain injury. Russian Journal of Phisiology. 2022;108(10):1264–1278 . EDN: DVCGKV doi: 10.31857/s0869813922100077

[46] Фомичева Е.Е., Шанин С.Н., Филатенкова Т.А., и др. Коррекция поведенческих нарушений и состояния микроглии рекомбинантным антагонистом рецептора IL-1 при экспериментальной черепно-мозговой травме // Российский физиологический журнал им. И.М. Сеченова. 2022. Т. 108, № 10. С. 1264–1278. EDN: DVCGKV doi: 10.31857/s0869813922100077

[47] Rybakina EG, Shanin SN, Fomicheva EE, et al. Violations of interaction between immune and neuroendocrine systems in stress, chronic fatigue syndrome and ways of their correction. Medical Academic Journal. 2010;10(4):161–174. EDN: TJECUP

[48] Рыбакина Е.Г., Шанин С.Н., Фомичева Е.Е., и др. Нарушения взаимодействия иммунной и нейроэндокринной систем при стрессе, синдроме хронической усталости и способы их коррекции // Медицинский академический журнал. 2010. Т. 10, № 4. С. 161–174. EDN: TJECUP

[49] Fomicheva EE, Shanin SN, Filatenkova TA, et al. Serotoninergic system in development of neuroimmune interaction impairments under experimental modeling of chronic fatigue. Vestnik of Saint Petersburg University. Medicine. 2015;(3):5–14. EDN: UXNQKR

[50] Фомичева Е.Е., Шанин С.Н., Филатенкова Т.А., и др. Серотонинергическая система мозга в развитии нарушений нейроиммунного взаимодействия при моделировании хронической усталости // Вестник Санкт-Петербургского университета. Медицина. 2015. № 3. С. 5–15. EDN: UXNQKR

[51] Rybakina EG, Shanin SN, Fomicheva EE, Korneva EA. Cellular and molecular mechanisms of interaction between the immune and neuroendocrine systems in chronic fatigue syndrome in an experiment. Russian Journal of Phisiology. 2009;95(12):1324–1335. EDN: OJCFYZ

[52] Рыбакина Е.Г., Шанин С.Н., Фомичева Е.Е., Корнеева Е.А. Клеточные и молекулярные механизмы взаимодействия иммунной и нейроэндокринной систем при синдроме хронической усталости в эксперименте // Российский физиологический журнал им. И.М. Сеченова. 2009. Т. 95, № 12. С. 1324–1335. EDN: OJCFYZ

[53] Fomicheva EE, Filatenkova TA, Rybakina EG. Activity of the hypothalamic-pituitary-adrenocortical system during the induction of chronic fatigue syndrome in an experiment. Russian Journal of Phisiology. 2009;95(1):11–18. EDN: OJBRHL

[54] Фомичева Е.Е., Филатенкова Т.А., Рыбакина Е.Г. Активность гипоталамо-гипофизарно-адренокортикальной системы при индукции синдрома хронической усталости в эксперименте // Российский физиологический журнал им. И.М. Сеченова. 2009. Т. 95, № 1. С. 11–18. EDN: OJBRHL

[55] Ifuku M, Hossain SM, Noda M, Katafuchi T. Induction of interleukin-1β by activated microglia is a prerequisite for immunologically induced fatigue. Eur J Neurosci . 2014;40(8):3253–3263 . doi: 10.1111/ejn.12668

[56] Ifuku M., Hossain S.M., Noda M., Katafuchi T. Induction of interleukin-1β by activated microglia is a prerequisite for immunologically induced fatigue // Eur J Neurosci. 2014. Vol. 40, N 8. P. 3253–3263. doi: 10.1111/ejn.12668

[57] Katafuchi T, Kondo T, Take S, Yoshimura M. Brain cytokines and the 5-HT system during poly I:C-induced fatigue. Ann N Y Acad Sci. 2006;1088:230–237. doi: 10.1196/annals.1366.020

[58] Katafuchi T., Kondo T., Take S., Yoshimura M. Brain cytokines and the 5-HT system during poly I:C-induced fatigue // Ann N Y Acad Sci. 2006. Vol. 1088. P. 230–237. doi: 10.1196/annals.1366.020

[59] Sjöström EO, Culot M, Leickt L, et al. Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier. Brain Behav Immun Health. 2021;16:100307. doi: 10.1016/j.bbih.2021.100307

[60] Sjöström E.O., Culot M., Leickt L., et al. Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier // Brain Behav Immun Health. 2021. Vol. 16. P. 100307. doi: 10.1016/j.bbih.2021.100307

[61] Chmielewski G, Majewski MS, Kuna J, et al. Fatigue in inflammatory joint diseases. Int J Mol Sci. 2023;24(15):12040. doi: 10.3390/ijms241512040

[62] Chmielewski G., Majewski M.S., Kuna J., et al. Fatigue in inflammatory joint diseases // Int J Mol Sci. 2023. Vol. 24, N 15. P. 12040. doi: 10.3390/ijms241512040

[63] Field R, Campion S, Warren C, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010;24(6):996–1007. doi: 10.1016/j.bbi.2010.04.004

[64] Field R., Campion S., Warren C., et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration // Brain Behav Immun. 2010. Vol. 24, N 6. P. 996–1007. doi: 10.1016/j.bbi.2010.04.004

[65] Vandestadt C, Vanwalleghem GC, Khabooshan MA, et al. RNA-induced inflammation and migration of precursor neurons initiates neuronal circuit regeneration in zebrafish. Dev Cell . 2021;56(16):2364–2380.e8. doi: 10.1016/j.devcel.2021.07.021

[66] Vandestadt C., Vanwalleghem G.C., Khabooshan M.A., et al. RNA-induced inflammation and migration of precursor neurons initiates neuronal circuit regeneration in zebrafish // Dev Cell. 2021. Vol. 56, N 16. P. 2364–2380.e8. doi: 10.1016/j.devcel.2021.07.021

RIGHTS & PERMISSIONS

Eco-Vector